Amarin | AMRN - Cash And Equivalent

Stock Price
14.66
Daily Change
-0.08 -0.54%
Monthly
0.55%
Yearly
79.66%
Q2 Forecast
14.28

Amarin reported $122.8M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novartis USD 9.56B 2.9B Sep/2025